As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside
Early Data Suggests Superiority Against Pain Crises
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
You may also be interested in...
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.